Clinical Development of Formulated Therapeutic and Prophylactic DNA-based Vaccines - (PPT)

摘要

Safety: All vaccine doses were well tolerated; No discontinuations due to vaccination/adverse events; Adverse events typically resolved in a few days; No vaccine-related clinical or laboratory serious adverse events; Most common reactions: Injection site pain, headache, malaise, myalgia Immune responses; Monovalent cohorts; HI antibody response rates from 47%-67%; Peak titers by day 56, sustained titers to day 182 in 33%-50%; HI antibody responses in the reported range of protein-based vaccines; H5 T-cell responses in 75%-100% sustained for at least 6 months.